Drug Profile


Alternative Names: ACT-334441; lysosphingolipid receptor agonist - Idorsia; S1P1 receptor modulator - Idorsia; Second selective S1P1 receptor agonist - Idorsia; Sphingosine 1 phosphate receptor modulators - Idorsia; Sphingosine 1-phosphate receptor 1 agonists - Idorsia

Latest Information Update: 27 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Idorsia Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Lysosphingolipid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus

Most Recent Events

  • 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
  • 16 Jun 2017 Actelion Pharmaceuticals spun off its drug discovery operations and early-stage clinical development assets into a newly created company, Idorsia
  • 22 May 2017 Actelion Pharmaceuticals plans a phase III trial for Systemic lupus erythematosus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top